581813-17-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-4-(trifluoromethyl)benzoic acid serves as a crucial building block in the synthesis of a variety of drugs and pharmaceutical products. Its unique structure contributes to the development of new medicinal compounds, enhancing their therapeutic potential.
Used in Chemical Research:
In the realm of chemical research, 3-Bromo-4-(trifluoromethyl)benzoic acid is employed as an intermediate in organic synthesis. It aids in the creation of complex organic molecules, facilitating advancements in chemical science and technology.
Safety Considerations:
it is imperative to handle 3-Bromo-4-(trifluoromethyl)benzoic acid with care and adhere to proper safety protocols to ensure the well-being of individuals and the integrity of the environment.

InChI:InChI=1S/C8H4BrF3O2/c9-6-3-4(7(13)14)1-2-5(6)8(10,11)12/h1-3H,(H,13,14)

Upstream product

• 126541-81-9 methyl 3-nitro-4-(trifluoromethyl)benzoate 
• 2363-16-8 methyl 4-bromo-3-nitrobenzoate 
• 586-76-5 4-Bromobenzoic acid 
• 6319-40-0 4-bromo-3-nitrobenzoic acid 
• 126541-82-0 3-Amino-4-(trifluormethyl)benzoesaeure-methylester 
• 116965-16-3 3-nitro-4-(trifluoromethyl)benzoic acid 
• 125483-00-3 3-amino-4-(trifluoromethyl)benzoic acid 

Downstream Products

• 581813-18-5 3-bromo-4-(trifluoromethyl)benzamide 
• 581813-19-6 3-bromo-4-(trifluoromethyl)benzylamine 
• 1383618-46-9 6-ethoxy-2-(3-(pyridin-2-yl)-4-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin 
• 1383625-02-2 2-bromo-1-(3-bromo-4-(trifluoromethyl)phenyl)ethanone 

Relevant academic research and scientific papers

TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to bicyclic heteroaryl benzamide compounds of formulas (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES

Disclosed are compounds of formula (I): (Formula (I) where X, Y, X, A, R1; R2, and R3 are defined herein. Also disclosed are pharmaceutically acceptable salts of the compounds, compositions containing the compounds, and methods of using the compounds to treat, e.g., cancer.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.